Immunoglobulin Market Size (2024 - 2029)

Immunoglobulin Market Analysis

The Global Immunoglobulin Market size is expected to grow from USD 14,482.11 million in 2023 to USD 20,607.86 million by 2028, at a CAGR of 7.31% during the forecast period.

The COVID-19 pandemic has increased demand for immunoglobulin products to help boost the immune response and fight off the infection. For instance, according to an article published by the Frontiers Journal in February 2023, it was found that long-term high-dose immunoglobulin therapy was an effective treatment option for COVID-19 patients. Therefore, the adoption of immunoglobulin therapy surged during the pandemic, thereby burgeoning the market growth. Furthermore, the demand for immunoglobulins is projected to remain high during the post-pandemic period due to the long-term health effects of COVID-19. Post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID, could result in persistent symptoms or conditions that require ongoing treatment, including immunoglobulins. Therefore, looking at the overall scenario, it was observed that the COVID-19 pandemic had a significant impact on the market studied.

The major factors driving the market growth include increased immunodeficiency disease prevalence and a surging number of drug launches by prominent players. Immunoglobulins are crucial in managing immunodeficiency diseases by supplementing deficient antibodies, preventing infections, improving immune function, and managing autoimmune manifestations. Intravenous Immunoglobulins (IVIG) replace the missing antibodies and thereby aid in preventing recurrent infections. Hence, with the rising burden of immunodeficiency disorders, the market is expected to grow significantly during the forecast period. For instance, as per the article published by BioMed Central Ltd in March 2022, the prevalence of Common Variable Immunodeficiency (CVID) in the same population was approximately 16.6% in the United States, 22.5% in Canada, and 34.2% in Australia in 2021. The high prevalence of CVID and improved diagnosis and awareness have increased the demand for immunoglobulin therapies. In addition, immunoglobulin therapy plays a significant role in managing Myasthenia Gravis (MG). Immunoglobulins temporarily improve muscle function and relieve MG symptoms by blocking pathogenic autoantibodies targeting acetylcholine receptors and modulating the immune response. Hence, the rising prevalence of MG is projected to drive market growth during the forecast period. For instance, as per an article published by the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in November 2022, MG is a chronic neuromuscular autoimmune disease that can cause life-threatening muscle weakness, affecting approximately 56,000 to 123,000 people in Europe annually. Therefore, the high prevalence of MG is projected to create high demand for immunoglobulin therapeutics during the forecast period.

Moreover, the active participation of government organisations in the launch of various advanced immunoglobulin therapeutics is also projected to drive market growth during the forecast period. For instance, in August 2022, Argenx received the European (EC) marketing authorisation grant for VYVGART (efgartigimod alfa-fcab), a human IgG1 antibody fragment, as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

Thus, the market is expected to project significant growth over the forecast period due to the rising prevalence of immunodeficiency disorders such as Common Variable Immunodeficiency and myasthenia gravis and the number of product launches by prominent players. However, stringent government regulations and the high cost of therapy are expected to impede market growth during the study period.

Immunoglobulin Industry Segmentation

As per the scope of the report, immunoglobulin, also referred to as an antibody, is a protein produced by plasma cells and other lymphocytes. It is a complex entity that exerts its immunomodulatory effect on different immune system components. It is obtained from the blood through the process of fractionation and is purified for therapeutic and non-therapeutic applications. The Immunoglobulin Market is Segmented by Product (IgG, IgA, IgM, IgE, and IgD), Mode of Delivery (Intravenous and Subcutaneous), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the abovementioned segments.